Drug Database · Clinicians

Cefaclor

Brands (52) Ceclor, Ceflor, Ephron…Show all

Antibacterial (cephalosporin); Antibacterial (second generation cephalosporin); and others PH FDA category

Dose usually unchangedRx · Prescription drug107 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 224af904-38f3-4210-a750-e21006db4c66, version date November 1, 2022 (Cefaclor · Azorian Pharma, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus…
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains.

Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes Note: Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present.

Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

  • Known allergy to cephalosporins
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

CONTRAINDICATIONS Cefaclor is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Dosing: Adult

  • Adults: 250 mg every 8 hours; doubled for more severe infections (such as pneumonia) or less susceptible organisms
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Cefaclor is administered orally. Adults -- The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled. Pediatric Patients -- The usual recommended daily dosage for pediatric patients is 20 mg/kg/day in divided doses every 8 hours.

In more serious infections, otitis media, and infections caused by less susceptible organisms, 40 mg/kg/day are recommended, with a maximum dosage of 1 g/day. Table 1: Cefaclor for Oral Suspension, USP 20 mg/kg/day Weight 125 mg/5 mL 250 mg/5 mL 9 kg 1/2 tsp t.i.d. 18 kg 1 tsp t.i.d. 1/2 tsp t.i.d. 40 mg/kg/day 9 kg 1 tsp t.i.d. 1/2 tsp t.i.d. 18 kg 1 tsp t.i.d.

B.I.D. Treatment Option —For the treatment of otitis media and pharyngitis, the total daily dosage may be divided and administered every 12 hours. Table 2: Cefaclor for Oral Suspension, USP 20 mg/kg/day (Pharyngitis) Weight 375 mg/5 mL 18 kg 1/2 tsp b.i.d. 40 mg/kg/day (Otitis Media) 9 kg 1/2 tsp b.i.d. 18 kg 1 tsp b.i.d.

Cefaclor may be administered in the presence of impaired renal function. Under such a condition, the dosage usually is unchanged (see PRECAUTIONS). In the treatment of β-hemolytic streptococcal infections, a therapeutic dosage of cefaclor should be administered for at least 10 days. Directions for Mixing: Add appropriate water volume as indicated in the following table in two portions to dry mixture in the bottle.

Shake well after each addition. Each 5 mL (approximately one teaspoonful) will then contain Cefaclor, USP, monohydrate equivalent to 250 mg anhydrous cefaclor, respectively, as shown in the following table. Oversize bottle provides extra space for shaking. Table 3: Cefaclor For Oral Suspension, USP Strength Package Size (when mixed) Water Volume to Add Anhydrous Cefaclor/5 mL (approx. one teaspoonful) 250 mg/5 Ml 150 mL 106 mL 250 mg

Dosing: Altered kidney function

Cefaclor is 60% to 85% excreted unchanged in urine, but its half-life rises only from about 0.6–0.9 hours to 2.3–2.8 hours even with no kidney function. The US label says it may be given in kidney impairment with the dose usually unchanged. Hemodialysis shortens the half-life by 25% to 30%.

Kidney function measure: Label gives no kidney measure or bands.

Show full dosing details
CrCl ≥60 mL/min
No dose change (label).
CrCl 30–59 mL/min
Dose usually unchanged (label). Watch for toxicity, as cefaclor is substantially excreted by the kidney (label geriatric use).
CrCl 15–29 mL/min
Dose usually unchanged (label). Watch for toxicity, as cefaclor is substantially excreted by the kidney (label geriatric use).
CrCl <15 mL/min (not on dialysis)
Dose usually unchanged (label). Watch for toxicity, as cefaclor is substantially excreted by the kidney (label geriatric use).
Hemodialysis (intermittent)
No dialysis dosing in label; hemodialysis shortens the half-life by 25% to 30% (label). Specialist input.
Peritoneal dialysis
No peritoneal dialysis dosing in label. Specialist input.
CRRT
Not in label; the cited CRRT review (Li 2020) gives no regimen for this drug. Specialist input.
  • Dialyzable? Partly: hemodialysis shortens the half-life by 25% to 30% (label); not shown to help in overdose.
  • Monitoring Kidney function in older adults (label); diarrhea (CDAD); serum-sickness-like reactions in children.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
No pediatric kidney dosing in label; adult label: dose usually unchanged.
eGFR 30–59
No pediatric kidney dosing in label; adult label: dose usually unchanged.
eGFR 15–29
No pediatric kidney dosing in label; adult label: dose usually unchanged.
eGFR <15 (not on dialysis)
No pediatric kidney dosing in label; adult label: dose usually unchanged.
Hemodialysis (intermittent)
No pediatric dialysis data. Specialist input.
Peritoneal dialysis
No pediatric dialysis data. Specialist input.
CRRT
No pediatric CRRT data in the cited sources. Specialist input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Dosage and administration (renal excerpts) US FDA label

Cefaclor may be administered in the presence of impaired renal function.

Dosing: Pediatric

Approved ages
Children (label dosing by weight).
Usual dose
20 mg/kg/day divided every 8 hours; serious infections and otitis media 40 mg/kg/day; otitis media and pharyngitis may be divided every 12 hours (label).
Maximum dose
1 g/day (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness of this product for use in infants less than 1 month of age have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use Of the 3,703 patients in clinical studies of cefaclor, 594 (16.0%) were 65 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney (see CLINICAL PHARMACOLOGY), and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION).

Dosage forms

Philippines

  • Granule for suspension: 50 mg/mL, 125 mg/5 mL, 250 mg/5 mL
  • Powder for suspension: 50 mg/mL, 125 mg per 5 mL, 125 mg/5 mL, 250 mg per 5 mL, 250 mg/5 mL
  • Capsule: 250 mg, 500 mg
  • Powder for oral suspension: 50 mg/mL, 125 mg/5 mL, 250 mg/5 mL
  • Extended-release tablet: 375 mg, 750 mg
  • Granule for oral suspension: 50 mg/mL
  • Granule for suspension strawberry flavor: 50 mg/mL

Registered products in the Philippines

107 products registered with the Food and Drug Administration (FDA) Philippines list Cefaclor as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products107
Philippine FDA-registered products for Cefaclor
Package insert
AclorCefaclor (as monohydrate)
125 mg/5 mL Granules for SuspensionHDPE Plastic Bottle in 60 mL
Rx
Lloyd Laboratories, Inc.Bulacan
Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc.
DR-XY33948
Nov 9, 2032
AclorCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc.
DRP-086-02
Mar 25, 2027
AclorCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with medicine dropper x 10 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc.
DRP-4613-01
Mar 15, 2030
AczebriCefaclor(as monohydrate)
250 mg CapsuleAlu-Clear PVC Blister Pack x 10’s (Box of 100’s)
Rx
Shin Poong Pharmaceutical Co., Ltd.Republic of Korea
Phil. Shinpoong Pharma, Inc.
DRP-3580
Jun 2, 2030
AndrecepCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionHDPE Bottle with Measuring Cup x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Philippine Home Pharmaceuticals
DR-XY38063
Jun 7, 2030
AndrecepCefaclor (as Monohydrate)
500 mg CapsuleClear PVC Blister Pack x 10's (Box of 50's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Philippine Home Pharmaceuticals
DR-XY39918
Aug 11, 2031
BercefCefaclor
250 mg/5 mL Granules for SuspensionHDPE Bottle with measuring cup x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Totalcare Pharma Inc.
DRP-3573-02
Feb 19, 2029
BercefCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle x 10 mL with dropper (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Totalcare Pharma Inc.Trader: Randril Internation Co., Inc.
DRP-3423-01`
Oct 3, 2028
BetaclorCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with medicine dropper x 10 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Southmed Pharma, CorporationTrader: Euro-Health Care Exponents, Inc.
DRP-4613-02
Mar 15, 2030
BioclocelCefaclor (as monohydrate)
125 mg/5 mL Granules for SuspensionHDPE Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Zeutica, Inc.
DR-XY35322
Jan 19, 2029
BioclocelCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)30 mL Capacity Amber Glass Bottle with Medicine Dropper x 10 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Zeutica, Inc.
DR-XY35383
Feb 3, 2029
CeclobidCefaclor (as monohydrate)
250 mg/5 mL Powder for Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
EL Laboratories, Inc.Laguna
Trader: The Cathay YSS Distributors Company, Inc.
DRP-3873
Mar 20, 2032
CeclobidCefaclor (as monohydrate)
50 mg/mL Powder for Suspension (Pediatric Oral Drops)Amber Glass Bottle x 20 mL w/ medicine dropper (Box of 1's)
Rx
EL Laboratories, Inc.Laguna
Trader: The Cathay YSS Distributors Company, Inc.
DRP-2101
Aug 9, 2032
CeclorCefaclor
125 mg/5 mL Powder for SuspensionAmber Glass Bottle with measuring cup x 60 mL (Box of 1's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Aspen Philippines Inc.
DRP-15731
May 8, 2030
CeclorCefaclor (as monohydrate)
250 mg/5 mL Powder for Suspension (Strawberry Flavor)Amber Glass Bottle with Measuring Cup x 60 mL (Box of 1's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Aspen Philippines, Inc.
DR-XY4009-L
May 21, 2029
CeclorCefaclor (as monohydrate)
50 mg / mL Granules for Suspension20 mL Amber Glass Bottle w/ medicine dropper (Box of 1's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Aspen Philippines, Inc.
DRP-15730
Dec 5, 2027
CeclorCefaclor (as monohydrate)
50 mg/mL Granules for Suspension20 mL Amber Glass Bottle w/ medicine dropper (Box of 1's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Aspen Philippines, Inc.
DR-XY18121
Dec 5, 2027
Ceclor DSCefaclor (as monohydrate)
250 mg/ 5 mL Powder for Suspension (Strawberry Flavor)Amber Glass Bottle with Measuring Cup x 60 mL (Box of 1's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Aspen Philippines Inc.
DRP-15732
May 21, 2029
CecrocefCefaclor (as monohydrate)
125 mg/5 mL Granules For SuspensionPlastic Bottle x 60 mL with Measuring Cup (Box of 1's)
Rx
J.M. TOLMANN LABORATORIES INC.Philippines
TGP PHARMA INC.
DRP-075-01
Jul 9, 2029
CecrocefCefaclor (As Monohydrate)
250mg/5mL Granules For SuspensionPlastic Bottle with Medicine cup x 60mL (Box of 1's)
Rx
J.M. TOLMANN LABORATORIES INC.Philippines
TGP PHARMA INC.
DRP-073-01
Jul 9, 2029
CecrocefCefaclor (As Monohydrate)
50 mg/mL Granules For Suspension (Oral Drops)Amber glass Bottle with medicine dropper x 10mL (Box of 1's)
Rx
J.M. Tolmann Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-2558-05
Oct 19, 2029
CefacCefaclor (as Monohydrate)
50 mg/mL Powder for Oral Suspension30 mL USP Type III amber glass bottle with 20 mm aluminum plain white cap (Box of 1's)
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-9462
Mar 8, 2028
CefacloxCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionWhite HDPE Plastic Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Bulacan
Eliset Pharmaceutical, Inc.Trader: Westfield Pharmaceuticals, Inc.
DRP-7620-03
Jul 18, 2031
CefaczamilCefaclor
125 mg/5 mL Powder for SuspensionPVDC Bottle x 60 mL (Box of 1's)
Rx
Geofman PharmaceuticalsPakistan
Sahar International Trading, Inc
DRP-3594
Oct 1, 2030
CefakorCefaclor (as monohydrate)
125 mg/5 mL Powder for Oral Suspension (Strawberry Flavor)White HDPE Bottle with PP Measuring Cup x 30 mL and 60 mL (Box of 1's)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15544
Jul 31, 2029
CefakorCefaclor (as monohydrate)
250 mg/5 mL Powder for Oral Suspension (Strawberry Flavor)White HDPE Bottle with PP Measuring Cup x 30 mL and 60 mL (Box of 1's)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15545
Jul 31, 2029
CefaquestCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's)
Rx
J.M. Tolmann Laboratories, Inc.Philippines
Health-Quest Pharma And Medical Supplies Trading
DRP-073-13
Jul 9, 2029
CefarCefaclor (As Monohydrate)
125 mg/5 mL Granules For SuspensionPlastic Bottle with medicine cup x 60mL (Box of 1's)
Rx
J.M. TOLMANN LABORATORIES INC.Philippines
WESTFIELD PHARMACEUTICALS, INC.
DRP-075-03
Jul 9, 2029
CefarCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Philippines
Westfield Pharmaceuticals, Inc.
DRP-073-04
Jul 9, 2029
CefarCefaclor (as Monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with Medicine Dropper x 10 ml (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Philippines
Westfield Pharmaceuticals, Inc.
DRP-2558-01
Oct 19, 2029
Cefasaph 500Cefaclor (as Monohydrate)
500 mg CapsuleAlu/Golden Yellow Colored PVC Blister Pack x 10's (Box of 10's)
Rx
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-4113
Nov 23, 2027
CefazenCefaclor (as monohydrate)
750 mg Extended-Release TabletFoil Strip x 10's Box of 100's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen’s Research, Inc.
DR-XY36211
Jul 8, 2029
CeflorCefaclor
125 mg/5 mL Powder for Suspension75 mL HDPE Bottle with LDPE cap and measuring cup x 60 mL (Box of 1’s)
Rx
Diamond Laboratories Inc.Philippines
Rilem Pharma Corp.
DRP-7564
Dec 1, 2031
CeflorCefaclor
250 mg/5 mL Powder for Suspension75 mL Capacity HDPE Bottle with LDPE Cap and Measuring Cup x 60 mL (Box of 1's)
Rx
Diamond Laboratories Inc.Philippines
Rilem Pharma Corp.
DRP-7562
Dec 1, 2031
CeflorCefaclor (as monohydrate)
50 mg / mL Powder for Oral Suspension (Oral Drops) (Strawberry Flavor)In 25 mL HDPE Plastic Bottle Box of 1's
Rx
Diamond Laboratories Inc.Philippines
Rilem Pharma Corp.
DRP-7069
Oct 18, 2027
CeflorCefaclor (as monohydrate)
500 mg CapsuleAlu-Clear PVC Blister Pack x 10's (Box of 50's & 100's)
Rx
Diamond Laboratories Inc.Philippines
Rilem Pharma Corp.
DRP-7158
Nov 12, 2027
CefmedCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Altomed Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-086
Mar 25, 2027
CefmedCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with medicine dropper x 10 mL net content in 15 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Altomed Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-4613
Mar 15, 2030
Ceftal DSCefaclor
125 mg/5 mL Powder for Oral Suspension30 mL LDPE Bottle (Box of 1's)
Rx
Sakar Healthcare Pvt. Ltd.India
Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4691
Sep 6, 2028
ClocelCefaclor (as monohydrate)
50 mg/mL Granules for Oral SuspensionHDPE Bottle x 15 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DR-XY44318
Mar 24, 2030
CloracefCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionHDPE Plastic Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DR-XY42680
Sep 26, 2028
CloranCefaclor (as monohydrate)
125 mg/ 5 mL Powder for SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Scheele Laboratories Phils., Inc.Philippines
—
DR-XY31605
Apr 10, 2028
ClorcefCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionHigh Density Polyethylene (HDPE) Bottle x 60 mL (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Philippines
Trader: IAE Pharmaceuticals Corporation
DR-XY32728
Dec 13, 2029
ClorcefCefaclor (as Monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle x 10 mL with Medicine Dropper (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Philippines
Trader: IAE Pharmaceuticals Corporation
DR-XY35703
Apr 21, 2029
ClorfilCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionWhite HDPE Plastic Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-7620
Jul 18, 2031
ClorgenCefaclor (as monohydrate)
125 mg/5 mL Granules for SuspensionPlastic Bottle with measuring cup x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Gamot Philippines, Inc.
DR-XY27986
Oct 25, 2027
ClorgenCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Gamot Philippines, Inc.
DR-XY27386
Mar 25, 2027
ClormedCefaclor (As Monohydrate)
125 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Philippines
Meedpharma Medical Supplies & Equipment Distributor
DRP-075-04
Jul 9, 2029
ClormedCefaclor (As Monohydrate)
250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine cup x 60mL (Box of 1's)
Rx
J.M. TOLMANN LABORATORIES INC.Philippines
MEEDPHARMA MEDICAL SUPPLIES & EQUIPMENT DISTRIBUTOR
DRP-073-06
Jul 9, 2029
CLORMEDCefaclor (As Monohydrate)
50 mg/mL Granules For Suspension (Oral Drops)Amber glass Bottle with medicine dropper x 10ml (Box of 1's)
Rx
J.M. Tolmann Laboratories, Inc.Philippines
Meedpharma Medical Supplies and Equipment Distributor
DRP-2558-02
Oct 19, 2029
ElceclorCefaclor (as Monohydrate)
125 mg/5 mL Granules for SuspensionPlastic Bottle x 60 mL with Measuring Cup (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Philippines
J:Khezznov Trading Industries Inc
DRP-075-08
Jul 9, 2029
ElceclorCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionWhite HDPE Plastic Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
J;Khezznov Trading Industries Inc.Trader: Westfield Pharmaceuticals, Inc.
DRP-7620-02
Jul 18, 2031
ELCECLORCefaclor (As Monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber glass bottle with medicine dropper x 10mL with measuring cup Box of 1's
Rx
J.M. Tolmann Laboratories, Inc.Philippines
J:Khezznov Trading Industries Inc.
DRP-2558-08
Oct 19, 2029
EliclorCefaclor (as Monohydrate)
250 mg/5 mL Powder for Suspension120mL Amber bottle x 60mL (Box of 1's)
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-1111
Sep 13, 2031
EphronCefaclor (as monohydrate)
125 mg/5 mL Granules for SuspensionPlastic Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma, Incorporated
DR-XY30707
May 11, 2030
EphronCefaclor (as monohydrate)
250 mg/5 mL Granules for Suspension (Orange Flavor)White Colored HDPE Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma, Inc.
DR-XY35636
Mar 24, 2029
EphronCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)15 mL Amber Glass Bottle x 10 mL (net content) with medicine dropper (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma, Incorporated
DR-XY29933
Sep 1, 2029
EphronCefaclor (as monohydrate)
500 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma Inc.
DR-XY29161
Nov 15, 2028
ErcefCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Quad-Gen PharmaceuticalsTrader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-1645-02
Mar 25, 2027
ErcefCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops) Strawberry Flavor10 mL in 15 mL Boston Round Amber Bottle with Plastic Dropper
Rx
Lloyd Laboratories, Inc.Philippines
Quad-Gen PharmaceuticalsTrader: Eadriex Pharmaceuticals Phils., Inc.
DRP-7827-01
Jan 2, 2027
FaclorCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionPlastic bottle with medicine cup x 60 mL (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Philippines
Frontida Pharmaceutical Incorporated
DRP-073-11
Jul 9, 2029
Klor-SCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionPlastic bottle with medicine cup x 60 mL (Box of 1's)
Rx
J.M. TOLMANN LABORATORIES INC.Philippines
STARPHARM, INC.
DRP-073-12
Jul 9, 2029
LorcefCefaclor (as monohydrate)
125 mg/5 mL Granules for Suspension60 mL Plastic Bottle per Box
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DR-XY27398
Mar 25, 2027
LorcefCefaclor (as monohydrate)
250 mg/5 mL Granules for Suspension60 mL Plastic Bottle
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DR-XY27567
Jun 7, 2027
NoneCefaclor (as monohydrate)
125 mg per 5 mL Powder for SuspensionAmber glass bottle x 30 mL (Box of 1's); Amber glass bottle x 105 mL (Box of 1's)
Rx
Asian Antibiotics, Inc.Philippines
Trader: Ritemed Phils., Inc.
DR-XY27801
Sep 5, 2027
NoneCefaclor (as monohydrate)
125mg/5mL Powder for Suspension60mL Amber glass bottle (Box of 1's)
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-5536
Jul 28, 2027
NoneCefaclor (as monohydrate)
125mg/5mL Powder for Suspension60mL Amber glass bottle Box of 1's
Rx
Drugmaker's Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-5536-01
Jul 28, 2027
NoneCefaclor (as monohydrate)
250 mg per 5 mL Powder for SuspensionAmber glass bottle x 30 mL (Box of 1's); Amber glass bottle x 105 mL (Box of 1's)
Rx
Asian Antibiotics, Inc.Philippines
Trader: Ritemed Phils., Inc.
DR-XY27802
Sep 5, 2027
NoneCefaclor
250 mg/5 mL Powder for Suspension120 mL Capacity Amber Glass Bottle (60 mL Net Content)
Rx
Drugmaker's Laboratories, Inc.Philippines
Trader: Terramedic, Inc.
DR-XY31691
May 4, 2028
NoneCefaclor (as monohydrate)
50 mg/ mL Powder for Suspension (Oral Drops)Amber glass bottle x 20 mL Box of 1's
Rx
Asian Antibiotics, Inc.Philippines
Trader: Ritemed Phils., Inc.
DR-XY27803
Sep 5, 2027
NoneCefaclor (as monohydrate)
500 mg CapsuleAluminum Foil Strip x 6's (Box of 30's)
Rx
Asian Antibiotics, Inc.Philippines
Trader: Ritemed Phils., Inc.
DR-XY27569
Jun 7, 2027
NoneCefaclor (as monohydrate)
500 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 50's)
Rx
Drugmaker's Laboratories, Inc.Philippines
Trader: Terramedic, Inc.
DR-XY31646
Apr 18, 2028
RemedlorCefaclor (As monohydrate)
250 mg / 5mL Granules for SuspensionBoston Round Amber Bottle x 60mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Remed Pharmaceuticals, Inc.
DRP-2908
Dec 2, 2030
REMEDLORCefaclor (as Monohydrate)
Granules for Suspension (Oral Drops) 50 mg/mLBoston Round Amber Bottle x20mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Remed Pharmaceuticals, Inc.
DRP-3780
Nov 24, 2030
RimaclorCefaclor (as monohydrate)
125 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals Phils., Inc.
DRP-1649
Mar 25, 2027
RimaclorCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL
Rx
Lloyd Laboratories, Inc.Philippines
Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals Phils., Inc.
DRP-1645
Mar 25, 2027
RimaclorCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)
Rx
Lloyd Laboratories, Inc.
Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-7827
Jan 2, 2027
SecosefCefaclor (as Monohydrate)
500 mg CapsuleBlister Pack x 10's (Box of 50's)
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-1071
Dec 2, 2030
SeflorCefaclor (As Monohydrate)
250 mg/5mL Granules For SuspensionPlastic Bottle with Medicine cup x 60 mL (Box of 1's)
Rx
J.M. TOLMANN LABORATORIES INC.Philippines
SEAMMED PHARMA
DRP-073-10
Jul 9, 2029
SHEMICLORCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's)
Rx
J.M. TOLMANN LABORATORIES INC.Philippines
TGIF PHARMACEUTICAL TRADING INC.
DRP-073-07
Jul 9, 2029
SurecefCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionHigh density Polyethylene (HDPE) bottle with measuring cup x 60 mL (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Philippines
Trader: Pharmacare Products Corporation
DR-XY33504
Jun 21, 2029
SurecefCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Metro Manila
Pharmacare Products Corporation
DRP-073-14
Jul 9, 2029
Surecef®Cefaclor
50 mg/mL Granules for Suspension (Oral Drops)Amber Bottle x 10 mL (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Philippines
Trader: Pharmacare Products Corporation
DR-XY35253
Dec 23, 2026
VefarolCefaclor (as Monohydrate)
125 mg/5 mL Granules for SuspensionLDPE Bottle x 60 mL with Measuring Cup (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Vamsler Phils. Incorporated
DRP-3846
Mar 25, 2027
VefarolCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionLDPE Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Vamsler Phils. Incorporated
DRP-3878
Mar 25, 2027
VerzatCefaclor (as monohydrate)
125 mg/5 mL Granules for SuspensionHDPE Bottle with measuring cup x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Randril Internation Co., Inc.
DRP-4243
Feb 19, 2029
VerzatCefaclor (as monohydrate)
250 mg/5 mL Granules for SuspensionHDPE Bottle with measuring cup x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Randril Internation Co., Inc.
DRP-3573
Feb 19, 2029
VerzatCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle x 10 mL ((Box of 1's))
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Randril Internation Co., Inc.
DRP-3423
Oct 3, 2028
Verzat-ERCefaclor (as Monohydrate)
375 mg Extended-Release TabletStrip Foil x 10's (Box of 10's)
Rx
Lloyd Laboratories, Inc.Philippines
Randril Internation Co., Inc.
DRP-650
Jul 18, 2031
VinsefCefaclor (as Monohydrate)
125 mg/5 mL Granules for SuspensionLDPE Bottle x 60 mL with Measuring Cup (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Ultramed Pharma, Inc.Trader: Vamsler Phils. Incorporated
DRP-3846-01
Mar 25, 2027
VinsefCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionLDPE Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Ultramed Pharma, Inc.Trader: Vamsler Phils. Incorporated
DRP-3878-01
Mar 25, 2027
XelentCefaclor (as Monohydrate)
125 mg/ 5 mL Powder for Oral SuspensionAmber Glass Bottle with measuring cup x 60 mL and 105 mL
Rx
Asian Antibiotics, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY25752
Dec 10, 2029
XelentCefaclor (As Monohydrate)
250 mg/ 5 mL Powder for Oral SuspensionAmber Glass Bottle with measuring cup 60 mL and 105 mL
Rx
Asian Antibiotics, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY25751
Dec 10, 2029
XelentCefaclor (As Monohydrate)
50 mg/ mL Powder for Suspension (Oral Drops)Amber Glass Bottle with medicine dropper x 20 mL (Box of 1's)
Rx
Asian Antibiotics, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY25754
Dec 10, 2029
XelentCefaclor (as monohydrate)
500 mg CapsuleFlex Foil x 6's (Box of 30's)
Rx
Asian Antibiotics, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY25753
Dec 10, 2029
XelorCefaclor
250 mg/5 mL Granules for SuspensionHDPE Bottle with measuring cup x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Metz Pharmaceuticals, Inc.
DRP-3573-01
Feb 19, 2029
XelorCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle x 10 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Metz Pharmaceuticals, Inc.Trader: Randril International Co., Inc.
DRP-3423-02
Oct 3, 2028
XeztronCefaclor (As Monohydrate)
125 mg/5 mL Granules For SuspensionPlastic Bottle x 60 mL with Measuring Cup (Box of 1's)
Rx
J.M. TOLMANN LABORATORIES INC.Philippines
—
DRP-075
Jul 9, 2029
XeztronCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's)
Rx
J.M. TOLMANN LABORATORIES INC.Philippines
—
DRP-073
Jul 9, 2029
XeztronCefaclor (As Monohydrate)
50mg/mL Granules For Suspension (Oral Drops)Amber Glass Bottle with medicine dropper x 10mL (Box of 1's)
Rx
J.M. Tolmann Laboratories, Inc.Philippines
—
DRP-2558
Oct 19, 2029
ZeflorCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Gamot Philippines, Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-086-03
Mar 25, 2027
ZeflorCefaclor (as Monohydrate)
250 mg/5 mL Granules for SuspensionLDPE Plastic Bottles x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
WeCare Pharma Corp.Trader: Euro-Health Care Exponents, Inc.
DRP-086-08
Mar 25, 2027
ZeflorCefaclor (as monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with medicine dropper 10 mL net content in 15 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
WeCare Pharma Corp.Trader: Euro-Health Care Exponents, Inc.
DRP-4613-04
Mar 15, 2030
ZifclorCefaclor (as Monohydrate)
50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with Medicine Dropper x 10 ml (Box of 1's)
Rx
J.M. Tolmann Laboratories Inc.Philippines
TGIF Pharmaceutical Trading Inc.
DRP-2558-03
Oct 19, 2029
ZyklorCefaclor (As Monohydrate)
250 mg/5 mL Granules For SuspensionPlastic Bottle with Medicine cup x 60mL (Box of 1's)
Rx
J.M. TOLMANN LABORATORIES INC.Philippines
AUSPICIA INC.
DRP-073-09
Jul 9, 2029
ZyrcefCefaclor
250 mg/5 mLGranules for SuspensionHDPE Bottle with measuring cup x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Basic Pharmaceutical Corp.
DRP-3573-03
Feb 19, 2029
ZyrcefCefaclor (as monohydrate)
500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 50's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Basic Pharmaceutical Corp.
DR-XY27981
Oct 24, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS BEFORE THERAPY WITH CEFACLOR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFACLOR, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN- SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.

IF AN ALLERGIC REACTION TO CEFACLOR OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPER-SENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.

Antibiotics, including cefaclor, should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to drugs. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Cefaclor for Oral Suspension, USP, and may range in severity from mild diarrhea to fatal colitis.

Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin- producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.

CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.

Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Drug interactions

Drug or classSeverityEffectWhat to do
Oral anticoagulants (warfarin)Adjust or monitorIncreased anticoagulant effect reported, rarely with bleeding (label).Monitor INR.
ProbenecidAdjust or monitorInhibits renal excretion of cefaclor (label).Expect higher cefaclor levels; monitor for adverse effects.
Aluminum- or magnesium-hydroxide antacidsAdjust or monitorReduce absorption of extended-release cefaclor tablets when taken within 1 hour of the dose; H2 blockers do not (extended-release label).Separate the antacid from an extended-release tablet by at least 1 hour.
Live oral typhoid vaccine (Ty21a, Vivotif)AvoidAntibiotics may act on the vaccine strain and prevent a protective immune response (Vivotif label).Do not give the vaccine during cefaclor treatment.
Intravesical BCG (TICE BCG)AvoidAntimicrobial therapy may interfere with the effectiveness of BCG (TICE BCG label).Postpone BCG instillations during cefaclor treatment.
Fecal microbiota spores (Vowst)AvoidContains bacterial spores; antibacterials should not be given at the same time (Vowst label).Finish cefaclor before starting Vowst; its label completes antibacterial treatment 2 to 4 days before the first dose.
Urine glucose tests (copper reduction: Benedict's, Fehling's, Clinitest)MinorFalse-positive urine glucose (label).Use glucose-oxidase tests instead.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Hypersensitivity rash (about 1.5%; morbilliform 1 in 100)
  • Diarrhea

Serious

  • Anaphylaxis
  • Serum-sickness-like reactions
  • Clostridioides difficile-associated diarrhea
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Adverse effects considered to be related to therapy with cefaclor are listed below: Hypersensitivity reactions have been reported in about 1.5% of patients and include morbilliform eruptions (1 in 100). Pruritus, urticaria, and positive Coombs' tests each occur in less than 1 in 200 patients. Cases of serum-sickness-like reactions have been reported with the use of cefaclor.

These are characterized by findings of erythema multiforme, rashes, and other skin manifestations accompanied by arthritis/arthralgia, with or without fever, and differ from classic serum sickness in that there is infrequently associated lymphadenopathy and proteinuria, no circulating immune complexes, and no evidence to date of sequelae of the reaction. Occasionally, solitary symptoms may occur, but do not represent a serum-sickness-like reaction.

While further investigation is ongoing, serum-sickness-like reactions appear to be due to hypersensitivity and more often occur during or following a second (or subsequent) course of therapy with cefaclor. Such reactions have been reported more frequently in pediatric patients than in adults with an overall occurrence ranging from 1 in 200 (0.5%) in one focused trial to 2 in 8,346 (0.024%) in overall clinical trials (with an incidence in pediatric patients in clinical trials of 0.055%) to 1 in 38,000 (0.003%) in spontaneous event reports.

Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy; occasionally these reactions have resulted in hospitalization, usually of short duration (median hospitalization = 2 to 3 days, based on postmarketing surveillance studies). In those requiring hospitalization, the symptoms have ranged from mild to severe at the time of admission with more of the severe reactions occurring in pediatric patients.

Antihistamines and glucocorticoids appear to enhance resolution of the signs and symptoms. No serious sequelae have been reported. More severe hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis have been reported rarely. Anaphylactoid events may be manifested by solitary symptoms, including angioedema, asthenia, edema (including face and limbs), dyspnea, paresthesias, syncope, hypotension, or vasodilatation.

Anaphylaxis may be more common in patients with a history of penicillin allergy. Rarely, hypersensitivity symptoms may persist for several months. Gastrointestinal symptoms occur in about 2.5% of patients and include diarrhea (1 in 70). Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.

(see WARNINGS). Nausea and vomiting have been reported rarely. As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic jaundice have been reported rarely. Other effects considered related to therapy included eosinophilia (1 in 50 patients), genital pruritus, moniliasis or vaginitis (about 1 in 50 patients), and, rarely, thrombocytopenia or reversible interstitial nephritis.

Causal Relationship Uncertain – CNS -- Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, and somnolence have been reported. Transitory abnormalities in clinical laboratory test results have been reported. Although they were of uncertain etiology, they are listed below to serve as alerting information for the physician.

Hepatic -- Slight elevations of AST, ALT, or alkaline phosphatase values (1 in 40). Hematopoietic -- As has also been reported with other β-lactam antibiotics, transient lymphocytosis, leukopenia, and, rarely, hemolytic anemia, aplastic anemia, agranulocytosis, and reversible neutropenia of possible clinical significance.

There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and Coumadin ® concomitantly. Renal -- Slight elevations in BUN or serum creatinine (less than 1 in 500) or abnormal urinalysis (less than 1 in 200). Cephalosporin-class Adverse Reactions In addition to the adverse reactions listed above that have been observed in patients treated with cefaclor, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: fever, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, hemorrhage, false-positive test for urinary glucose, elevated bilirubin, elevated LDH, and pancytopenia.

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated (see DOSAGE AND ADMINISTRATION and OVERDOSAGE sections).

To report SUSPECTED ADVERSE REACTIONS, contact Azorian Pharma at 1- 302-459-8479 or FDA at 1-800-FDA-1088 or www.fda.gov/me. dwatch

Monitoring parameters

  • Kidney function in older adults (label); diarrhea (CDAD); serum-sickness-like reactions in children. Kidney
  • Kidney function in older adults
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects: Pregnancy Category B Reproduction studies have been performed in mice and rats at doses up to 12 times the human dose and in ferrets given 3 times the maximum human dose and have revealed no harm to the fetus due to cefaclor. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Small amounts of cefaclor have been detected in mother's milk following administration of single 500 mg doses. Average levels were 0.18, 0.20, 0.21, and 0.16 mcg/mL at 2, 3, 4, and 5 hours, respectively. Trace amounts were detected at 1 hour. The effect on nursing infants is not known. Caution should be exercised when cefaclor is administered to a nursing woman.

Pharmacokinetics

Key PK parameters

Half-life0.6 to 0.9 hour
Half-life in kidney failure (ESKD) kidney2.3 to 2.8 hours with no kidney function (label)
Renal excretion kidney60% to 85% unchanged in urine within 8 hours
Dialyzability kidneyPartly (half-life shortened 25% to 30%)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours.

The serum half-life in normal subjects is 0.6 to 0.9 hour.

In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged.

In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours.

Excretion pathways in patients with markedly impaired renal function have not been determined.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Cefaclor is well-absorbed after oral administration to fasting subjects. Total absorption is the same whether the drug is given with or without food; however, when it is taken with food, the peak concentration achieved is 50% to 75% of that observed when the drug is administered to fasting subjects and generally appears from three-fourths to 1 hour later.

Following administration of 250 mg, 500 mg, and 1 g doses to fasting subjects, average peak serum levels of approximately 7, 13, and 23 mcg/mL, respectively, were obtained within 30 to 60 minutes. Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours.

During this 8-hour period, peak urine concentrations following the 250 mg, 500 mg and 1 g doses were approximately 600, 900 and 1,900 mcg/mL, respectively. The serum half-life in normal subjects is 0.6 to 0.9 hour. In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours.

Excretion pathways in patients with markedly impaired renal function have not been determined. Hemodialysis shortens the half-life by 25% to 30%. Microbiology Mechanism of Action As with other cephalosporins, the bactericidal action of cefaclor results from inhibition of cell-wall synthesis. Mechanism of Resistance Resistance to cefaclor is primarily through hydrolysis of beta-lactamases, alteration of penicillin-binding proteins (PBPs) and decreased permeability.

Pseudomonas spp., Acinetobacter calcoaceticus and most strains of Enterococci (Enterococcus faecalis, group D streptococci), Enterobacter spp., indole-positive Proteus, Morganella morganii (formerly Proteus morganii), Providencia rettgeri (formerly Proteus rettgeri), and Serratia spp. are resistant to cefaclor. Cefaclor is inactive against methicillin-resistant staphylococci. β-lactamase-negative, ampicillin-resistant strains of H. influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility to this agent.

Antibacterial Activity Cefaclor has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Gram-positive Bacteria Staphylococcus aureus (methicillin susceptible only) Coagulase negative staphylococci (methicillin susceptible only) Streptococcus pneumoniae Streptococcus pyogenes (group A β-hemolytic streptococci) Gram-negative Bacteria Escherichia coli Haemophilus influenzae (excluding β-lactamase-negative, ampicillin-resistant strains) Klebsiella spp.

Proteus mirabilis The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentrations (MICs) less than or equal to the susceptible breakpoint of cefaclor. However, the safety and effectiveness of cefaclor in treating clinical infections due to these bacteria has not been established in adequate and well-controlled trials.

Gram-negative Bacteria Citrobacter diversus Moraxella catarrhalis Neisseria gonorrhoeae Anaerobic Bacteria Bacteroides spp. Peptococcus spp. Peptostreptococcus spp. Propionibacterium acnes Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Cefaclor · Azorian Pharma, LLC [US FDA-approved label, version 1, November 1, 2022]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=224af904-38f3-4210-a750-e21006db4c66
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Azorian Pharma, LLC. (2022). Cefaclor for oral suspension, USP [Prescribing information; US FDA-approved label, ANDA065412, set ID 224af904-38f3-4210-a750-e21006db4c66, version effective November 1, 2022]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=224af904-38f3-4210-a750-e21006db4c66
  4. Teva Pharmaceuticals USA, Inc. (2019). Cefaclor extended-release tablets USP [Prescribing information; US FDA-approved label, set ID 0878bdc2-0410-4938-9890-96523aa81c2f, version effective July 31, 2019]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0878bdc2-0410-4938-9890-96523aa81c2f
  5. Typhoid vaccine live oral Ty21a (Vivotif) [Prescribing information; US FDA label, set ID 31fe1e75-da67-4e6d-a529-8b82905dad45, version effective March 18, 2011; Warnings]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31fe1e75-da67-4e6d-a529-8b82905dad45
  6. Merck Sharp & Dohme LLC. (2026). TICE BCG (BCG live, for intravesical use) [Prescribing information; US FDA label, set ID c9b74876-e665-442b-87ad-b7333bc9a67a, version effective February 20, 2026; Warnings]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9b74876-e665-442b-87ad-b7333bc9a67a
  7. Aimmune Therapeutics, Inc. (2026). VOWST (fecal microbiota spores, live-brpk) capsules [Prescribing information; US FDA label, set ID 99e5a37a-930c-4641-bcdd-7013ec1c15fe, version effective April 23, 2026; sections 2.1 and 7]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e5a37a-930c-4641-bcdd-7013ec1c15fe

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 18, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .